# CULENER  
## Report Analysis  
**Author:** Opeoluwa Shodipe  

---

## Table of Contents

1. [Analyzed Assay](#1-analyzed-assay)  
2. [Analysis](#2-analysis)  
   - [2.1 Analytical Sensitivity](#21-analytical-sensitivity)  
   - [2.2 Processing Time / Throughput](#22-processing-time--throughput)  
3. [Scoring Table](#3-scoring-table)  
4. [References](#4-references)  

---

## 1. Analyzed Assay

This study aims to evaluate the methodologies outlined by **Bennis et al. (2018)** for the extraction of DNA from skin lesion biopsies of *Cutaneous Leishmaniasis (CL)* suspected cases. Additionally, **PCR and RFLP analysis** will be carried out to detect and identify *Leishmania spp.* targeting the internal transcribed spacer 1 (**ITS1**) of the ribosomal DNA.

---

## 2. Analysis

All assessments together must cover the entire **Target Product Profile (TPP)**.

> âš ï¸ *Note: TPP criteria are interlinked. Ensure coherence across sections.*

---

### 2.1 Analytical Sensitivity

**Criterion**  
Assess the analytical sensitivity of the PCR assay using samples from **200 clinically suspected CL patients** in West Nepal between **June 2024 â€“ May 2026**.

**Responsible Scientist:** Opeoluwa Shodipe

**Analysis**  
DNA was extracted from lysate samples using the **phenol-chloroform method**, and ITS1 PCR detected **0.2 parasite/reaction**, equivalent to **20â€“40 picograms/reaction** (Nasereddin et al., 2008).

*In silico* analysis using **LITSR and L5.8S primers** showed limited specificity to *Leishmania siamensis*. Primer-BLAST returned only one result with other *Leishmania spp.*, and BLAST of that FASTA sequence yielded only 33 hits. This suggests **limited sensitivity/specificity for L. siamensis**, likely due to **insufficient sequence data in GenBank**.

> ðŸ“Œ *Bennis et al. (2018) did not provide analytical sensitivity data.*

**Conclusion**  
Despite high sensitivity reported using ITS1 PCR, RDT methods are not validated for this context. **Further assessment** is required.

---

### 2.2 Processing Time / Throughput

**Criterion**  
Assess processing time for each batch of samples sent every 3 months from **June 2024 to August 2026**.

**Responsible Scientist:** Opeoluwa Shodipe

**Analysis**  
- **ITS1 PCR + RFLP** require ~3 hours to analyze positive reaction products.  
- Full processing (DNA extraction, PCR, and RFLP) requires **2â€“2.5 days** (SchÃ¶nian et al., 2003).  

**Conclusion**  
Processing **25 samples every 3 months** is feasible. Based on the **target population**, **available manpower**, and **resource constraints**, batches of 25 samples will comfortably meet the study timeline, with all samples processed by **August 2026**.

---

## 3. Scoring Table

Use the following scale:

- **A** â€“ 100% certainty that the requirement is met. No validation needed.  
- **C** â€“ Likely fits the TPP but needs validation.  
- **E** â€“ Definitely does not meet the requirement.  

| **Criterion**              | **Acceptable Requirement** | **Optimal Requirement** |
|---------------------------|----------------------------|--------------------------|
| Analytical Sensitivity     | C                          | D                        |
| Processing Time / Throughput | A                        | A                        |

---

## 4. References

- Bennis I, Verdonck K, El Khalfaoui N, Riyad M, Fellah H, Dujardin JC, Sahibi H, Bouhout S, Van der Auwera G, Boelaert M (2018). *Accuracy of a rapid diagnostic test based on antigen detection for the diagnosis of cutaneous Leishmaniasis in patients with suggestive skin lesions in Morocco*. *Am J Trop Med Hyg* **99(3)**: 716â€“722.

- Nasereddin, A., Bensoussan-Hermano, E., SchÃ¶nian, G., Baneth, G., Jaffe, C.L. (2008). *Molecular diagnosis of Old World cutaneous leishmaniasis and species identification by use of a reverse line blot hybridization assay.* *J Clin Microbiol*, **46**, 2848â€“2855.

- SchÃ¶nian G, Nasereddin A, Dinse N, Schweynoch C, Schallig H, Presber W, et al. (2003). *PCR diagnosis and characterization of Leishmania in local and imported clinical samples.* *Diagn Microbiol Infect Dis*, **47**, 349â€“358.

---

**Document Version:** MID-2024  
**Pages:** 2 of 2
